BiotechTube

CaPre + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Feb 1, 2018 → Jan 9, 2020

NCT ID
NCT03361501

About CaPre + Placebo

CaPre + Placebo is a phase 3 stage product being developed by Grace Therapeutics for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03361501. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT03361501Phase 3Completed
NCT03398005Phase 3Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
LY3875383 + PlaceboEli LillyPhase 1
33
ZYH7 + ZYH7 + ZYH7 + FenofibrateZydus LifesciencesPhase 2
52
Solbinsiran + PlaceboEli LillyPhase 2
52
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
77
warfarin + omefas + omega-3-acid ethyl estersAstraZenecaPhase 1
33
rosuvastatinAstraZenecaApproved
85
Simvastatin + acetylsalicylic acid (ASA) + omefasAstraZenecaPhase 1
33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
33
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
65
Epanova + LovazaAstraZenecaPhase 1
33
Epanova + Olive OilAstraZenecaPhase 3
77
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
77
ABT-143 + simvastatinAstraZenecaPhase 3
77
MaravirocPfizerPhase 1
32
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
76
IcosapentMochida PharmaceuticalPhase 3
76

Other Products from Grace Therapeutics

GTX-104 + Nimotop 30 MG Oral CapsulePhase 3
69
CaPre + PlaceboPhase 3
69
CaPre (TM) + CaPre (TM)Phase 2
44
Lipid Lowering MedicationPhase 2
44
GTX-104 + Nimodipine CapsulesPhase 1
25